Program
TNP-2092
Also written as “TNP-2092 capsules”, “TNP-2092 for injection” and “[14C]-TNP-2092”.
Its studies are mostly in Hyperammonemia · Gram-Positive Bacterial Infections, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| TenNor Therapeutics (Suzhou) | 30 open or running | phase 2since Nov 13, 2023 | Nov 13, 2023 | none ahead |
| TenNor Therapeutics | 31 open or running | phase 2since Mar 14, 2025 | Mar 22, 2024 | Jan 2027phase 2 · NCT06889701 |
| TenNor Therapeutics | 30 open or running | phase 2since Apr 30, 2019 | Apr 30, 2019 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 30, 2019First study: phase 2 study in Gram-Positive Bacterial InfectionsNew to TenNor TherapeuticsTenNor Therapeutics · NCT03964493 · 120 enrolled · United States
- Feb 25, 2020Phase 1 study in Prosthetic Joint InfectionTenNor Therapeutics · NCT04294862 · 13 enrolled · United States
- Sep 29, 2021Phase 1 study in HealthyTenNor Therapeutics · NCT05074134 · 6 enrolled · United States
- Nov 13, 2023TenNor Therapeutics (Suzhou)'s first study: phase 2 study in HyperammonemiaNew to TenNor Therapeutics (Suzhou)TenNor Therapeutics (Suzhou) · NCT06135675 · 36 enrolled · China
- Dec 7, 20232 phase 1 studiesTenNor Therapeutics (Suzhou) · NCT06178718, NCT06190340
- Mar 22, 2024TenNor Therapeutics's first study: phase 1 study in Helicobacter Pylori InfectionNew to TenNor TherapeuticsTenNor Therapeutics · NCT06337604 · 20 enrolled · China
- Apr 27, 2024Phase 1 study in Acute Bacterial Skin and Skin Structure Infection (ABSSSI)TenNor Therapeutics · NCT06394518 · 32 enrolled · China
- Mar 14, 2025Phase 2 study in Periprosthetic Joint Infection (PJI)TenNor Therapeutics · NCT06889701 · 33 planned · China
Ahead
- Jan 2027Primary completion: phase 2 study in Periprosthetic Joint Infection (PJI)TenNor Therapeutics · NCT06889701
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Bacterial DNA-directed RNA polymerase inhibitor; Bacterial DNA gyrase inhibitor; Topoisomerase IV inhibitor”ChEMBL 37, by rule
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06889701Periprosthetic Joint Infection (PJI) · China | 2 | Recruiting | TenNor Therapeutics | Jan 2027 | 33 |
| NCT06394518Acute Bacterial Skin and Skin Structure Infection (ABSSSI) · China | 1 | Completed | TenNor Therapeutics | Feb 24, 2023 | 32 |
| NCT06337604Helicobacter Pylori Infection · China | 1 | Completed | TenNor Therapeutics | Nov 23, 2017 | 20 |
| NCT06190340Helicobacter Pylori Infection · China | 1 | Completed | TenNor Therapeutics (Suzhou) | Sep 26, 2017 | 40 |
| NCT06178718Hyperammonemia · China | 1 | Completed | TenNor Therapeutics (Suzhou) | Aug 2, 2016 | 58 |
| NCT06135675Hyperammonemia · China | 2 | Completed | TenNor Therapeutics (Suzhou) | Jun 16, 2021 | 36 |
| NCT05074134Healthy · United States | 1 | Completed | TenNor Therapeutics | Nov 30, 2021 | 6 |
| NCT04294862Prosthetic Joint Infection · United States | 1 | Completed | TenNor Therapeutics | Dec 31, 2021 | 13 |
| NCT03964493Gram-Positive Bacterial Infections · United States | 2 | Completed | TenNor Therapeutics | Sep 28, 2020 | 120 |
How it is read
Names in the registry
- “TNP-2092 capsules”, 4 entries
- “TNP-2092 for injection”, 2 entries
- “TNP-2092”, 2 entries
- “[14C]-TNP-2092”, 1 entry
Conditions, from the studies’ own filings
- Hyperammonemia, 2 studies
- Gram-Positive Bacterial Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.